Evidence method
Level · gp.fundamentals.debt_to_revenue
42.97% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
TGTX · Dec 31, 2023
TG THERAPEUTICS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001437749-24-006144General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.00% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-13.44% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
8290.02% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
17.04% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
93.95% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
8.83% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
32.61% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
16.23% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History17 statesSelf-history eligible
Jun 30, 20220/7 normalizedLevel 3Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20235/7 normalizedLevel 3Sep 30, 20235/8 normalizedLevel 3Dec 31, 20235/9 normalizedLevel 3Mar 31, 20244/7 normalizedLevel 3Jun 30, 20245/7 normalizedLevel 3Sep 30, 20245/7 normalizedLevel 3Dec 31, 20246/8 normalizedLevel 3Mar 31, 20257/8 normalizedLevel 3Jun 30, 20257/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 59.65%
- Current
- 42.97%
- Delta
- -16.68%
- Previous
- 50.48%
- Current
- -13.44%
- Delta
- -63.92%
- Previous
- 176298.94%
- Current
- 8290.02%
- Delta
- -168008.92%
- Previous
- 20.24%
- Current
- 17.04%
- Delta
- -3.19%
- Previous
- 97.88%
- Current
- 93.95%
- Delta
- -3.93%
- Previous
- 69.22%
- Current
- 8.83%
- Delta
- -60.39%
- Previous
- 8.90%
- Current
- 32.61%
- Delta
- 23.71%
- Previous
- 5.55%
- Current
- 16.23%
- Delta
- 10.69%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · TGTX Fundamental State →Has State · TG THERAPEUTICS, INC. →Transitioned To · TGTX Fundamental State →Transitioned To · TGTX BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · TGTX CASH_GENERATION_DECREASED →Transitioned To · TGTX GROWTH_DECREASED →Transitioned To · TGTX INVENTORY_PRESSURE_DECREASED →Transitioned To · TGTX MARGIN_DECREASED →Transitioned To · TGTX PROFITABILITY_DECREASED →Transitioned To · TGTX R_AND_D_INTENSITY_INCREASED →Transitioned To · TGTX SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.